|
[1] WATKINS PB,SEEFF LB. Drug-induced liver injury:Summary of a single topic clinical research conference[J]. Hepatology,2006,43(3):618-631.
|
|
[2] LEISE MD,POTERUCHA JJ,TALWALKAR JA. Drug-induced liver injury[J]. Mayo Clin Proc,2014,89(1):95-106.
|
|
[3] HAN D,DARA L,WIN S,et al. Regulation of drug-induced liver injury by signal transduction pathways:Critical role of mitochondria[J]. Trends Pharmacol Sci,2013,34(4):243-253.
|
|
[4] HYASHI PH. Drug-Induced Liver Injury Network:Causality assessment,criteria,and experience in the United States[J].Int J Mol Sci,2016,17(2):201.
|
|
[5] DANAN G,TESCHKE R. RUCAM in drug and herb induced liver injury:The update[J]. Int J Mol Sci,2016,17(1):14.
|
|
[6] NAVARRO VJ,BARNHART HX,BONKOVSKY HL,et al. 167Herbal and dietary supplement induced hepatotoxicity in the U. S.[J]. Gastroenterology,2012,142(5):S-41.
|
|
[7] BNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol,1990,11(2):272-276.
|
|
[8] DANAN G,BENICHOU C. Causality assessment of adverse reactions to drugs———I. A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injuries[J]. J Clin Epidemiol,1993,46(11):1323-1330.
|
|
[9] MARIA VA,VICTORINO RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis[J].Hepatology,1997,26(3):664-669.
|
|
[10] DAS S,BEHERA SK,XAVIER AS,et al. Agreement among different scales for causality assessment in drug-induced liver injury[J]. Clin Drug Investig,2018,38(3):211-218.
|
|
[11] TSUTSUI A,NAKANUMA Y,TAKAGUCHI K,et al. Comparison of liver biopsy findings with the digestive disease week Japan 2004 scale for diagnosis of drug-induced liver injury[J].Mediators Inflamm,2015,2015:913793.
|
|
[12] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966; quiz 967.
|
|
[13] BHARADWAJ M,ILLING P,THEODOSSIS A,et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex[J]. Annu Rev Pharmacol Toxicol,2012,52:401-431.
|
|
[14] CIRULLI ET,NICOLETTI P,ABRAMSON K,et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury[J]. Gastroenterology,2019,156(6):1707-1716. e2.
|
|
[15] LI C,RAO T,CHEN X,et al. HLA-B*35∶01 Allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology,2019,70(1):346-357.
|
|
[16] TAJIRI K,SHIMIZU Y. Practical guidelines for diagnosis and early management of drug-induced liver injury[J]. World J Gastroenterol,2008,14(44):6774-6785.
|
|
[17] NICOLETTI P,AITHAL GP,BJORNSSON ES,et al. Association of liver injury from specific drugs,or groups of drugs,with polymorphisms in HLA and other genes in a genome-wide association study[J]. Gastroenterology,2017,152(5):1078-1089.
|
|
[18] ACKERSON T,AMBERG A,ATZRODT J,et al. Mechanistic investigations of the liver toxicity of the free fatty acid receptor1 agonist fasiglifam(TAK875)and its primary metabolites[J]. J Biochem Mol Toxicol,2019,33(8):e22345.
|
|
[19] NORMAN BH,FISHER MJ,SCHIFFLER MA,et al. Identification and mitigation of reactive metabolites of 2-aminoimidazole-containing microsomal prostaglandin E synthase-1 inhibitors terminated due to clinical drug-induced liver injury[J]. J Med Chem,2018,61(5):2041-2051.
|
|
[20] IJIRI Y,KATO R,SADAMATSU M,et al. Contributions of caspase-8 and-9 to liver injury from CYP2E1-produced metabolites of halogenated hydrocarbons[J]. Xenobiotica,2018,48(1):60-72.
|
|
[21] MARIA GM,MAURIZIO S,MASSIMO G,et al. Optimizing diagnostic approach to drug-induced liver injury[J]. Ital J Med,2018,12(3):180-189.
|
|
[22] URRUTIA-MALDONADO E,ALS-PALMER M,MUOZ DE RUEDA P,et al. The relation between activator and inhibitor killer-cell immunoglobulin-like receptors(KIRs)and hepatotoxicity in oncological treatment[J]. Minerva Pediatr,2019.[Epub ahead of print]
|
|
[23] KLEINER DE. Histopathological challenges in suspected drug-induced liver injury[J]. Liver Int,2018,38(2):198-209.
|
|
[24] Branch of Hepatobiliary Diseases,China Association of Chinese Medicine,Branch of Chinese Patent Medicine,China Association of Chinese Medicine. Guidelines for the clinical management of herb-induced liver injury[J]. J Clin Hepatol,2016,32(5):835-843.(in Chinese)中华中医药学会肝胆病分会，中华中医药学会中成药分会．中草药相关肝损伤临床诊疗指南[J]．临床肝胆病杂志，2016,32(5):835-843.
|
|
[25] LEFKOWITCH JH. The pathology of acute liver failure[J]. Adv Anat Pathol,2016,23(3):144-158.
|
|
[26] POPPER H,RUBIN E,CARDIOL D,et al. Drug-induced liver disease:A penalty for progress[J]. Arch Intern Med,1965,115:128-136.
|
|
[27] HU XQ. Re-discussion on histopathological score of druginduced liver injury[J]. J Hepatol,2014,19(8):577-579.(in Chinese)胡锡琪．药物性肝损伤组织病理学评分再探讨[J]．肝脏，2014,19(8):577-579.
|
|
[28] KLEINER DE,CHALASANI NP,LEE WM,et al. Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J]. Hepatology,2014,59(2):661-670.
|
|
[29] WANG T,ZHAO X,SHAO C,et al. A proposed pathologic sub-classification of drug-induced liver injury[J]. Hepatol Int,2019,13(3):339-351.
|
|
[30] DANIELIDES IC,CONSTANTOULAKIS M,DAIKOS GK. Hepatitis on high dose isoniazid:Reintroduction of the drug in severe tuberculous meningitis[J]. Am J Gastroenterol,1983,78(6):378-380.
|
|
[31] MOCTEZUMA-VELZQUEZ C,ABRALDES JG,MONTANO-LOZA AJ. The use of statins in patients with chronic liver disease and cirrhosis[J]. Curr Treat Options Gastroenterol,2018,16(2):226-240.
|
|
[32] BELLI C,ZUIN M,MAZZARELLA L,et al. Liver toxicity in the era of immune checkpoint inhibitors:A practical approach[J]. Crit Rev Oncol Hematol,2018,132:125-129.
|
|
[33] MITCHELL JR,LONG MW,THORGEIRSSON UP,et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy[J]. Chest,1975,68(2):181-190.
|
|
[34] ORTEGA-ALONSO A,ANDRADE RJ. Chronic liver injury induced by drugs and toxins[J]. J Dig Dis,2018,19(9):514-521.
|
|
[35] BNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol,1990,11(2):272-276.
|
|
[36] FONTANA RJ,WATKINS PB,BONKOVSKY HL,et al. Drug-Induced Liver Injury Network(DILIN)prospective study:Rationale,design and conduct[J]. Drug Saf,2009,32(1):55-68.
|
|
[37] MEDINA-CALIZ I,ROBLES-DIAZ M,GARCIA-MUOZ B,et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J]. J Hepatol,2016,65(3):532-542.
|
|
[38] TUJIOS SR,LEE WM. Acute liver failure induced by idiosyncratic reaction to drugs:Challenges in diagnosis and therapy[J]. Liver Int,2018,38(1):6-14.
|
|
[39] BJRNSSON E,OLSSON R. Outcome and prognostic markers in severe drug-induced liver disease[J]. Hepatology,2005,42(2):481-489.
|
|
[40] MENNECOZZI M,LANDESMANN B,PALOSAARI T,et al. Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro?[J]. PLo S One,2015,10(4):e0122786.
|
|
[41] SCHWINGE D,CARAMBIA A,QUAAS A,et al. Testosterone suppresses hepatic inflammation by the downregulation of IL-17,CXCL-9,and CXCL-10 in a mouse model of experimental acute cholangitis[J]. J Immunol,2015,194(6):2522-2530.
|
|
[42] AMACHER DE. Female gender as a susceptibility factor for drug-induced liver injury[J]. Hum Exp Toxicol,2014,33(9):928-939.
|
|
[43] ZHU J,SEO JE,WANG S,et al. The Development of a database for herbal and dietary supplement induced liver toxicity[J]. Int J Mol Sci,2018,19(10):2955.
|
|
[44] CHALASANI N,REDDY K,FONTANA RJ,et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to caucasians[J]. Am J Gastroenterol,2017,112(9):1382-1388.
|
|
[45] ZHU Y,NIU M,WANG JB,et al. Predictors of poor outcomes in 488 patients with herb-induced liver injury[J]. Turk J Gastroenterol,2019,30(1):47-58.
|
|
[46] MARTINEZ MA,VUPPALANCHI R,FONTANA RJ,et al. Clinical and histologic features of azithromycin-induced liver injury[J]. Clin Gastroenterol Hepatol,2015,13(2):369-376. e3.
|
|
[47] CHALASANI N,BONKOVSKY HL,FONTANA R,et al. Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J]. Gastroenterology,2015,148(7):1340-1352. e7.
|
|
[48] LEI CJ,WU LP. Clinical types and biochemical indexes in patients with drug-induced liver failure[J/CD]. Chin J Liver Dis(Electr Version),2018,10(1):70-73.(in Chinese)雷创杰，吴柳萍．药物性肝衰竭患者的临床分型及生物化学指标的差异[J/CD]．中国肝脏病杂志(电子版)，2018,10(1):70-73.
|
|
[49] VUPPALANCHI R,GOTUR R,REDDY KR,et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome[J]. Clin Gastroenterol Hepatol,2014,12(9):1550-1555.
|
|
[50] MEDINA-CALIZ I,GARCIA-CORTES M,GONZALEZ-JIMENEZ A,et al. Herbal and dietary supplement-induced liver injuries in the spanish DILI registry[J]. Clin Gastroenterol Hepatol,2018,16(9):1495-1502.
|
|
[51] JING J,TESCHKE R. Traditional Chinese medicine and herb-induced liver injury:Comparison with drug-induced liver injury[J]. J Clin Transl Hepatol,2018,6(1):57-68.
|
|
[52] BJRNSSON ES,GUNNARSSON BI,GRNDAL G,et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol,2015,13(3):602-608.
|
|
[53] WEI G,BERGQUIST A,BROOMU,et al. Acute liver failure in Sweden:Etiology and outcome[J]. J Intern Med,2007,262(3):393-401.
|
|
[54] REUBEN A. Hy’s law[J]. Hepatology,2004,39(2):574-578.
|
|
[55] JEONG R,LEE YS,SOHN C,et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury[J]. Scand J Gastroenterol,2015,50(4):439-446.
|
|
[56] WANG S,SHANGGUAN Y,DING C,et al. Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury[J]. J Int Med Res,2018:300060518811512.
|
|
[57] CHURCH RJ,KULLAK-UBLICK GA,AUBRECHT J,et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort[J]. Hepatology,2019,69(2):760-773.
|
|
[58] BJRNSSON E,KALAITZAKIS E,OLSSON R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury[J]. Aliment Pharmacol Ther,2007,25(12):1411-1421.
|
|
[59] BONKOVSKY HL,BARNHART HX,FOUREAU DM,et al. Cytokine profiles in acute liver injury-Results from the US DrugInduced Liver Injury Network(DILIN)and the Acute Liver Failure Study Group[J]. PLo S One,2018,13(10):e0206389.
|
|
[60] CHURCH RJ,KULLAK-UBLICK GA,AUBRECHT J,et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort[J]. Hepatology,2019,69(2):760-773.
|
DownLoad: